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Abstract
Background: Parasite resistance to the anti-malarial drug chloroquine is common in eastern Sudan. Dynamic
within-host changes in the relative abundance of both sensitive and resistant Plasmodium falciparum parasites
were examined in a cohort of chloroquine-treated patients presenting with uncomplicated falciparum malaria,
using a novel allele-specific quantitative approach.
Methods: Treatment outcomes were determined for 93 patients of all ages in a per protocol cohort using a
modified 14-day WHO protocol. Parasite DNA samples at days 0, 1, 2, 3, 7 and 14 following treatment were
analysed using real-time quantitative PCR methods that distinguished resistant and sensitive genotypes at amino
acids 72 - 76 of the pfcrt locus.
Results: Chloroquine treatment was not efficacious, and of 93 assessable patients, only 10 individuals (10.7%; 95%
C.I. 4.34 - 17.2%) enjoyed an adequate clinical and parasitological response. Resistant parasites with the haplotype
CVIET at codons 72-76 of the pfcrt locus were dominant in the starting population. Chloroquine sensitive parasites
with the haplotype CVMNK were detected in 19 individuals prior to treatment (20.43%; 95% C.I. 5.14 - 18.5%). In
these patients, CQ treatment rapidly selected CVIET parasites, and this haplotype overwhelmingly dominated the
parasite population in each individual by day 2 after treatment.
Conclusions: Such rapid intra-host selection of particular genotypes after the introduction of drug will cause
frequent misidentification of parasite genotypes present in the starting population. This will have a potentially
serious confounding effect on clinical trials which employ PCR-corrected estimates of treatment failure, as resistant
parasites below the detection threshold in the pre-treatment sample can be erroneously classified as “new”
infections during follow-up, over-estimating drug efficacy.
Background
The malaria parasite Plasmodium falciparum causes
considerable morbidity and mortality in the tropics, exa-
cerbated in the last decade of the 20
th century by wide-
spread drug resistance in endemic areas [1]. Resistance
to chloroquine, the cheapest and most widely available
anti-malarial, has reached significantly high levels lead-
ing to replacement with artemisinin-based combination
therapy (ACT) in many malaria-endemic countries [2].
Genetically, chloroquine resistance (CQR) has been
linked to 15 polymorphisms in the pfcrt gene from
different parts of the world [3-6], as well as mutations
in pfmdr1 [7,8]. Of particular interest are mutations in
the region of pfcrt encompassing codons 72 - 76. Substi-
tutions in the wild type allele, encoding CVMNK, give
rise to several resistant variants, of which the most com-
mon are CVIET in South-East Asia and Africa and
SVMNT, which has been reported in South America [3]
and Asia [9], but rarely in Africa [10]. The single codon
change at position 76, found in all natural CQR isolates
to date, is widely accepted as the best molecular marker
for field surveys of CQR P. falciparum. Prolonged use of
chloroquine monotherapy has imposed high selection
pressure, leading to a substantial increase in the preva-
lence of this marker in parasite populations worldwide. * Correspondence: colin.sutherland@lshtm.ac.uk
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many endemic countries, it is important from an epide-
miological point of view to monitor changes in fre-
quency at all loci associated with CQR as the effect of
decreased chloroquine pressure on the parasite popula-
tion is felt. Longitudinal measurements of the preva-
lence of CQR loci in a highly seasonal setting suggest
that sudden reduction in the intensity of CQ drug pres-
sure after the malaria transmission season and through
the dry (non-transmission) season can lead to signifi-
cantly lower prevalence of CQR parasites [11]. This sup-
ports other studies that have found evidence that CQR
parasites are intrinsically less fit than wild-type parasites
in the absence of CQ drug pressure [12,13]. Therefore,
the effects of the introduction of ACT in Sudan may be
dramatic, and could rapidly reduce the prevalence of
CQR parasites, as was seen in Malawi after removal of
CQ from the health system [14-16]. This selection may,
however, cause an increased parasite “tolerance” for
ACT [17,18].
Recently developed quantitative PCR (qPCR) techni-
ques employing dual-labelled probes allow for simulta-
neous allelic discrimination of two to six loci. This
technique has been found specific and sensitive in the
detection of drug resistance alleles of P. falciparum
[9,19,20]. Moreover the ability to quantify the abun-
dance of each allele in mixed genotype infections allows
detailed study of the dynamics of competition between
parasites with and without CQR alleles.
In this study, allele-specific quantification is employed
to study the abundance of parasites with wild-type and
CQ resistant genotypes at positions 72 - 76 of pfcrt in
Sudanese malaria patients before and after treatment
with CQ. Samples were collected during a clinical study
in 2004, immediately before the deployment of ACT in
Sudan, and provide detailed evidence of the intra-host
dynamics of parasites under CQ treatment in this highly
seasonal transmission setting prior to a dramatic change
in drug pressure.
Methods
In vivo study
Sample size
T h es a m p l es i z ew a sc a l c u l a t ed using EPINFO software
on the basis of the expected proportion of pfcrt-76T in
the population of 70% in eastern Sudan [12,21]. At a
confidence level of 95%, a study with 100 patients was
predicted to give 80% power to detect a difference in
treatment outcome between infections harbouring para-
sites with resistant versus sensitive pfcrt alleles.
Study area
Eastern Sudan is characterized by a markedly seasonal,
short malaria transmission season lasting a few weeks
every year. CQR has been reported since the mid 1980s
[22] and further studies indicate that this phenotype is
well established in the area [23,24]. Levels of CQR are
reported to be higher than other parts of the country
[21].
Patient recruitment
Symptomatic patients in Asar village were recruited into
a community-based CQ anti-malarial clinical study. The
WHO protocol for monitoring in vivo anti-malarial effi-
cacy recommends 28-days of follow-up [25], however a
1 4 - d a yp r o t o c o lw a sf o l l o w e da sf a i l u r er a t e sw e r e
anticipated to be high. The study included all age
groups, as adults are equally susceptible to infection in
this low endemicity setting.
Patients diagnosed with uncomplicated P. falciparum
mono-infection and who had axillary temperatures of
37.5°C or above were eligible to participate in the study.
Patients meeting all enrolment criteria as per established
study protocols [25], who did not have any other dis-
ease, and who provided their written informed consent
were recruited into the trial. A standard three-day dose
of chloroquine (25 mg/kg, IDA, Netherlands) was pro-
vided by the study team under observation. Patients
were observed for 30 minutes after treatment. If vomit-
ing occurred within 30 minutes of treatment, a full dose
was repeated. If vomiting occurred between 31 min and
one hour after treatment, half a dose was repeated.
Patients with persistent vomiting were referred to
Gedaref Teaching Hospital for appropriate treatment
and withdrawn from the study. Pregnant women were
referred to Gedaref Teaching Hospital. Patients who
refused to participate in the study or decided to with-
draw were provided with a regimen of three daily doses
o fa r t e s u n a t ep l u sas i n g l ed o s eo fs u l p h a d o x i n e -
pyrimethamine on day 0, as recommended by the
national malaria control programme.
Once enrolled the patient was given a follow-up sche-
dule for attending the clinic, on days 1, 2, 3, 7 and 14
after treatment. Thick and thin blood films were pre-
pared and blood drops on filter paper were collected on
each follow-up day. Parasite count was carried out
against 200 WBCs and parasite densities were calculated
assuming a WBC count of 6,000/μl.
Patients and their guardians were also advised to
return to the clinic if they developed any symptoms on
any other day during the study. Patients with recurrent
malaria symptoms from day 3 or later during follow-
up were withdrawn from the study and treated with
artesunate plus sulphadoxine-pyrimethamine as above.
A number of patients with low density asymptomatic
parasitaemia at day 3 were not identified as parasite
positive in the field clinic during follow-up and were
seen again on day 7. Subsequent, definitive microscopy
found day 3 parasites in blood films from these indivi-
duals. Therefore, these patients were retrospectively
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additional collection of a day 7 sample. All samples
collected contributed to the genetic analysis. At no
stage did the study objectives override the patients’
health and safety.
Sample collection and storage
Blood films for parasite count were collected and exam-
ined by microscopists on days 0, 1, 2, 3, 7 and 14 or on
any other day if required, a parallel drop of blood was
collected onto filter paper for DNA analysis.
Study end points
The in vivo study end points were taken directly from
the WHO 28-day protocol, adapted for 14 days follow-
up. The clinical endpoints were:
1) early treatment failure (ETF; parasitaemia on Day
2 higher than Day 0, parasitaemia on Day 3 with
axillary temperature ≥ 37.5°C; or persistent parasite
density greater than 25% of the presentation density
on days 1 or 2).
2) late clinical failure (LCF; recurrent symptoms with
parasitaemia on any day from 4 to 14)
3) late parasitological failure (axillary temperature ≥
37°C or history of fever or asymptomatic parasitae-
mia on day 7 to 14)
4) adequate clinical and parasitological response
(ACPR; parasitaemia absent days 3 to 14).
Quantitative real-time PCR (qPCR)
DNA was extracted from blood-spots as in previous stu-
dies [18], to yield approximately 100 μl of supernatant
containing DNA, which was stored at -20°C.
Double-labelled probes crt76-CVMNK, crt76-CVIET
and crt76-SVMNT were designed to detect the three
most common haplotypes at codons 72 to 76 of the
pfcrt gene. Each probe was dual-labelled with a reporter
dye at the 5’ end and a quencher moiety at the 3’ end
(Table 1). Previous studies described the use of this
assay for pfcrt genotyping of imported cases of falci-
parum malaria in the UK [9,26].
A2 5μl reaction volume contained 0.2 μMd N T P s ,
0.3 μM of each forward CRTD1 and reverse CRTD2 pri-
mer (Djimde, Doumbo et al. 2001), 0.1 μM of each
probe (MWG-Biotech), 1× (NH4)2SO4 reaction buffer, 3
mM MgCl2 and 1 unit of BIOTAQ™ DNA Polymerase
(Bioline).
DNA from 3D7, Dd2 and 7G8 clones, representing the
three most widespread pfcrt alleles CVMNK, CVIET and
SVMNT at codons 72-76 respectively, were obtained
from the Malaria Research & Reference Reagent
Resource (MR4, Manassas, Vermont, USA) and
employed to establish the technique and determine the
sensitivity and specificity of the assay. Genotypes were
identified by allelic discrimination analysis based on
which of the reporter dye signals accumulated in each
sample. Once established the technique was employed
in field samples to identify the corresponding alleles.
5 μl of DNA from each sample was added to the reac-
tion components and analysed as described above.
For qualitative experiments, a single multiplex PCR
reaction was run for each sample on each day of follow-
up. Relatively conservative thresholds were set manually,
by reference to the appropriate positive and negative
controls on each run.
For quantitative experiments, multiplex qPCR reac-
tions were run in triplicate for each sample and each
control. The increased precision afforded in these
experiments facilitated the setting of less conservative
thresholds, by reference to control DNA run in tripli-
cate. Relative quantitation was performed using a varia-
tion of the delta-delta CT (cycle threshold) method of
Price et al [27]. Briefly, DNA from the day 0 sample of
patient #57, which carried both CVMNK and CVIET
pfcrt alleles at relatively high abundance (mean CT for
CVMNK and CVIET of 27.12 and 26.26, respectively)
was selected as the calibrator and arbitrarily assigned a
relative value of 1.00. Relative abundance is then calcu-
lated as 2
-ΔΔCTw h e r eΔΔCT is equal to the mean over
three replicates of (CT
CVMNK -C T
CVIET)f o rt h et e s t
sample minus the mean of (CT
CVMNK -C T
CVIET)f o r
the calibrator sample (patient #57 day 0). All DNA sam-
ples from day 0, 1, 2 and 3 were then evaluated for
these 17 individuals and plotted on an arbitrary logarith-
mic scale from 0.0001 (CVMNK only) to 100.00 (CVIET
only). This relative allele abundance measure is a ratio
of the difference between the fluorophore signal for
each allele in the test sample, and that for the calibrator
sample, and thus has no units.
Sequencing
Forty field samples were randomly selected for direct
sequencing to evaluate the specificity of the real-time
Table 1 Double-labelled probes for pfcrt genotyping.
Probe 5’ Fluorophore Sequence 3’ Quencher
crt76-CVMNK FAM TGT GTA ATG AAT AAA ATT TTT GCT AA BHQ1
crt76-CVIET* JOE TGT GTA ATTG AA ACA ATT TTT GCT AA BHQ 2
crt76-SVMNT* ROX AGT GTA ATG AAT ACA ATT TTT GCT AA BHQ1
*Amino acid and nucleotide positions deviating from the wild-type are shown in bold.
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mers CRTP1 [4] and P6 5’-TCATTTTGGCCTTCA-
TAGGTCT-3’ in 25 of the samples while 15 samples
failed to produce a PCR product. These samples were
subjected to a hemi-nested PCR by CRTP1 and P8 5’-
GCCTGTATGCTTTTCAAACATG-3’ in the first round
a n dC R T P 1a n dP 6i nt h es e c o n dr o u n do fP C R .P C R
products were purified using the QIAquick PCR Purifi-
cation Kit (Qiagen, U.K). Sequencing was performed
using the BigDye
® Terminator v3.1 Cycle Sequencing
Kit (Applied Biosystems, USA) as recommended by the
manufacture and analysed by ABI 7300. Sequences were
viewed and edited in Chromas version 2.31 and aligned
in Bioedit sequence analysis software.
Data analysis
In vivo data were entered and analysed according to the
2003 WHO protocol for areas of low transmission, with
14 days follow-up [28]. Molecular data were analysed
using Stata 10 software package. Odds ratios were tested
for significance using Fisher’s exact test.
Ethical considerations
Ethical clearance was obtained from the National Ethical
Review Committee of the Federal Ministry of Health,
Sudan, the WHO/TDR Ethical Review Committee and
London School of Hygiene & Tropical Medicine Ethical
Review Committee.
Results
Study population
One hundred and five patients from Asar were recruited
to the study. Baseline characteristics for the study popu-
lation are shown in Table 2.
Efficacy of chloroquine in P. falciparum in Gedaref
105 patients were originally enrolled, twelve patients
either withdrew consent or were lost to follow-up, leav-
ing 93 in our per protocol analysis. Ninety-three (88.6%)
patients completed the CQ treatment course and
reached one of the study end-points. Four patients
(4.3%) with persisting symptoms and parasitaemia were
withdrawn and administered rescue treatment prior to
day 3. Ten patients (10.8%) exhibited adequate clinical
and parasitological response (ACPR). The remaining
patients failed treatment and these were classified using
standard WHO definitions (Table 3). Those with recur-
r e n tm a l a r i as y m p t o m sw e r eg i v e naf u l lc o u r s eo fr e s -
cue treatment.
Sensitivity and Specificity of the qPCR assay
The multiplexed qPCR assay was tested against a panel
of parasite clones obtained from the MR4 repository to
determine the specificity; 3D7 to represent the CVMNK,
Dd2 for CVIET and 7G8 for SVMNT haplotypes,
respectively. The qPCR assay detected the CVMNK at a
concentration as low as 0.003 ng/μl and the CVIET and
SVMNT at a concentration of 0.0003 ng/μl. Figure 1
shows the results for 3D7 (CVMNK) and Dd2 (CVIET).
Qualitative pfcrt allelic discrimination
Alleles at pfcrt codons 72 - 76 were successfully identi-
fied in 86 of 91 available pre-treatment (day 0) samples
by qPCR (5 samples failed to produce a detectable geno-
type). Among these, CVMNK was detected at day 0
(prior to treatment) in 19 infections (22.9%; 95% C.I.
13.7% - 32.1%), of which eleven were mixed infections
that also harboured detectable CVIET. The CVIET
allele, therefore, occurred in the vast majority of pre-
treatment infections. Wild-type alleles became less com-
mon during follow-up, occurring in 5, 4 and 1 of the
infections typed by qPCR at day 3, 7 and 14, respec-
tively. All but the last of these were mixed infections.
The SVMNT allele was not detected in any of the field
samples examined in this study by either qPCR or
sequencing. Carriage of pfcrt a l l e l e si ss u m m a r i z e di n
Figure 2. Patients displayed a number of different pat-
terns of allele carriage during follow-up, and a total of
more than 50 combinations were observed when treat-
ment outcome classification is also taken into account
(Figure 2).
The CVIET allele alone was carried throughout fol-
low-up by 60 patients, with the majority exhibiting
either early treatment failure (N = 50) or late treatment
Table 3 Classification of treatment outcome.
Classification Number %
ETF 61 64.5
LCF 7 7.5
LPF 11 11.8
ACPR 10 10.8
WITH 4 4.3
Total analysed 93 100
ETF: early treatment failure
LCF: late clinical failure
LPF: late parasitological failure
ACPR: adequate clinical and parasitological response
WITH: withdrawal.
Table 2 Base line characteristics of the study population.
Mean age yrs (min - max) 18.3 (5 - 76)
Female n (%) 54 (57.6)
Male n (%) 39 (42.4)
Mean temp °C day 0 (min - max) 37.8 (37.5 - 40.9)
Geometric mean parasitaemia day 0;
parasites/μl (95% C. I.)
2,305 (1,683 - 3,156)
Total completed follow-up 93
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allele CVMNK at enrolment, four were successfully trea-
ted, six were classed as late treatment failure, and seven
as early treatment failures; two were withdrawn. The
CQ-sensitive allele CVMNK was at low prevalence, and
carriage of this allele prior to treatment was not signifi-
cantly associated with overall treatment success (O.R.
2.32; 95% C.I. 0.332 - 12.4; p = 0.107 [2-sided Fisher’s
exact test]). However, the absence of CVMNK at enrol-
ment was specifically associated with ETF: of the 67
(86 - 19)evaluable individuals lacking CVMNK at pre-
sentation, 53 (74.7%) suffered ETF, compared to 7
(41.2%) of the 17 evaluable individuals carrying the wild-
type allele (O.R. 5.41; 95% C.I. 1.51 - 19.7; p = 0.002).
DNA sequencing of a 5’ segment of the pfcrt gene was
successfully performed in both forward and reverse
directions for 25 of 40 randomly selected day 0 parasite
DNA samples, using purified PCR products from a
single round of amplification. The results were in per-
fect agreement with those obtained by qPCR, including
one mixed infection, in which both alleles were dis-
cerned on both sequenced DNA strands.
Quantitative analysis of pfcrt allele abundance during CQ
treatment
In order to examine the selective effect of CQ upon para-
site genotypes, quantitative pfcrt allele-specific qPCR was
used to measure the relative abundance of CQ-resistant
genotypes in the few days immediately after treatment.
This is shown in detail for the nine individuals who har-
boured parasites carrying the wild-type pfcrt allele
CVMNK (alone or mixed with CVIET) at day 0, plus
eight individuals carrying only CVIET parasites (Figure 3).
Absolute quantification of these two genotypes would
require using a standardized volume of patient blood,
collected on identical filter-papers, and then extracted
Figure 1 Sensitivity of qPCR for detection of pfcrt alleles (CVMNK and CVIET) in P. falciparum DNA controls. The sensitivity of the qPCR
was tested in detecting serial dilutions of purified DNA from each control clone. Each control was prepared at a concentration of 3 ng/μl and in
ten-fold dilutions to 3 × 10
-4 ng/μl. Green fill represents a fluorescent signal above threshold in that channel, grey fill represents no detectable
signal above background. CT values are read from the x-axis of the plot, at the point at which the fluorescence curve crosses the threshold. Dd2:
CVIET. 3D7: CVMNK. NTC: no template control.
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blems in the field, at least two different types of filter
paper had been used for blood sample collection, and
DNA extraction from these two substrates may have dif-
fered in efficiency. Further, the volume of blood used in
each bloodspot was not measured. Therefore, absolute
quantification of parasites was not possible. To overcome
this, a relative allelic quantification method was devel-
oped based on the delta-delta Ct approach used to esti-
mate pfmdr1 copy number in P. falciparum ([27]; see
Methods). The results are plotted in Figure 3.
Each of the individuals with only CVMNK detected at
day 0 was found to carry CVIET parasites by day 3.
Two individuals initially typed as harbouring only
C V I E Tp r e s e n ta td a y0w e r ef o u n dt oa l s oh a v el o w
densities of CVMNK parasites present (patients #7, #63,
Figure 3B). An unexpected finding was the detection of
DNA from parasites of the CVMNK haplotype at low
abundance in all patients at day 2. This could not be
easily explained by technical problems with the assay -
all day two samples were repeated in three independent
assay runs, and both positive and negative controls in
each experiment gave the expected fluorescent signals.
A possible explanation is that sequestered developing
gametocytes and asexual parasites of the CVMNK geno-
type, not detectable in day 0 peripheral blood, are more
quickly lysed by CQ and the DNA released reaches
detectable levels on day 2 following treatment. However,
an unidentified technical error or contamination affect-
ing only these day 2 samples cannot be ruled out.
Figure 2 Diagrammatical representation of pfcrt allele carriage among trial participants during follow-up. Colours represent alleles
carried - green for CVMNK and orange for CVIET. White cells indicate PCR was performed but no pfcrt DNA was detected. Shaded cells indicate
no sample was taken/available. The SVMNT allele was not detected. Data collected were from single-tube assays of all available DNA samples
from each participant (N = 318 data points). A number of individuals without symptoms at Day 3 and with no parasites on initial slide-reading
were later found to have harboured parasites by definitive microscopy after completion of the trial. These individuals therefore contributed both
Day 3 and Day 7 samples to the analysis, despite being classified ETF.
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type were numerically dominant in all individuals except
those who presented with CVMNK parasites only on
day 0. On day 3, all individuals with parasites harboured
infections completely dominated by the CVIET haplo-
type. Therefore, as expected, rapid and profound within-
host selection against the CVMNK parasite haplotype
was observed in the 72 hours following the commence-
ment of chloroquine therapy. An important effect of
this selection is to confound the identification of recru-
descent parasites during follow-up. This effect is illu-
strated clearly by four individuals with only wild-type
CVMNK parasites detected on day 0 who later failed
treatment (Figure 2), and in particular by patients #22
and #91, analysed in detail in Figure 3A. The parasites
detectable in peripheral blood samples have changed
dramatically over the 48 hours following pre-treatment
sampling, with the disappearance of the CVMNK haplo-
type. All these individuals failed treatment at day 7 or
14, and would be identified as “new infections” when
compared against the day 0 sample only. The quantita-
tive analysis shows that in fact the CVIET parasites
appeared on day 1 or day 2 and so were certainly pre-
sent prior to treatment, but were not detected until the
introduction of drug to the parasite population had
rapidly changed the relative abundance of sensitive and
resistant parasites within each individual patient.
Discussion
Drug resistance has been a major challenge to control
programmes in sub-Saharan Africa for the past two
decades, and this precipitated the policy change in
Sudan from chloroquine to ACT as first-line treatment
for falciparum malaria. These new drugs are now killing
malaria parasites effectively, but may themselves be
threatened by the development of resistance in the
future, and so a thorough understanding of the selective
effects of anti-malarial drugs on P. falciparum popula-
tions in Sudan is crucial. Here the impact of chloro-
quine on parasites present in the Gedaref region is
reported, in the last transmission season before the
ACT policy was implemented. The relative abundance
of wild-type and chloroquine-resistant parasites was
measured and profound and rapid within-host selection
for resistant parasites in chloroquine-treated patients
quantified. Further studies will measure the effects of
ACT on these same parasite types in the seasons imme-
diately following the change in treatment policy in
Sudan.
In 2004, chloroquine was of almost no benefit for
patients with falciparum malaria in the study area. Only
10% of treated individuals in the trial enjoyed an ade-
quate clinical and parasitological response to treatment
over 14 days, and some of these remained parasite posi-
tive by PCR at days 7 or 14 (Figure 2). Longer follow-up
may have identified further clinical and parasitological
failures. It was possible to identify a handful of patients
harbouring drug-sensitive parasites prior to treatment,
but virtually all of these were found to harbour resistant
parasites later in follow-up. Detailed quantitative analysis
of these individuals demonstrated that this selection for
parasites of the CVIET genotype was rapid, such that
Figure 3 Detailed longitudinal analysis of relative abundance of CVMNK and CVIET for 17 selected patients. Group I: P. falciparum DNA
isolated from four patients carrying only wild-type parasites at day 0. Group II: DNA from seven patients carrying both wild-type and CQR
parasites at day 0. Group III: DNA from six patients carrying only CVIET parasites at day 0. Parasite DNA was analysed by qPCR to determine
relative abundance of CVIET alleles compared to CVMNK alleles in each sample from day 0 to day 3. The day 0 sample from isolate 57, with
similar CT values for both genotypes by qPCR, was selected as the comparator, and assigned an arbitrary value of 1.00. The relative abundance
of the CVIET allele was then determined (see Materials and Methods). Standard WHO 14 day treatment outcomes for each individual are given in
the legend of each panel: ACPR - adequate clinical and parasitological response (i.e. treatment success); WTH - withdrawn prior to day 3; ETF -
early treatment failure (parasites detected on day 3, regardless of symptoms); LCF - late clinical failure (day 7 or 14, with recurrent malaria
symptoms); LPF - late parasitological failure (day 7 or 14, without symptoms).
Gadalla et al. Malaria Journal 2010, 9:74
http://www.malariajournal.com/content/9/1/74
Page 7 of 10there were virtually no detectable CVMNK parasites in
most individuals by day 3 after treatment (Figure 3).
Particularly interesting were those individuals found to
harbour only CVMNK parasites prior to treatment, but
who subsequently failed treatment with CVIET parasites
present. This suggests that the presence of resistant
parasites among the starting population in these indivi-
duals was undetected by PCR, presumably because the
presence of minority genotypes is masked by the over-
whelming amplification of majority types. Chloroquine
resistance brings with it a reduced fitness relative to
wild-type parasites, which may mean they are out-com-
peted by wild-type parasites in untreated infections [11].
Thus only after drug insult enhances the relative fitness
of resistant parasites are they detectable in some indivi-
duals. This poses serious questions about the use of
genotyping to identify recrudescent parasites during the
follow-up of clinical trial participants [29], particularly
in situations in which drug resistant parasites are com-
mon, and are likely to be a minority population in a
proportion of infected individuals. In these circum-
stances, such resistant parasites may cause treatment
failure later in follow-up, but will be erroneously charac-
terized as “new infections” as their genetic fingerprint
will not have been detected in the pre-treatment sample.
Thus truly recrudescent, resistant parasites will not be
correctly identified. In the study described here, this
would have applied to four individuals, two classified as
late clinical failure, and two classified as late parasitolo-
gical failure (Figure 3). Although it is possible that a
more sensitive genotyping technique may have detected
these sub-populations at day 0, with any methodology
there will always be the possibility of parasite genotypes
circulating at a density below the limit of detection that
will be missed by a single sampling approach. This
assertion is supported by recent data from Nsobya et al
[30], who demonstrated by expansion of parasite isolates
in vitro that PCR genotyping of a single sample taken
prior to treatment does not adequately represent all the
genotypes present.
An unexpected finding was that a low abundance of
parasites of the CVMNK genotype was detected in the
majority of individuals at day 2 after treatment (data not
shown). In all PCR-positive individuals at this point,
CVIET genotypes were numerically dominant (Figure 3).
A technical failing of the assay due to DNA contamina-
tion was suspected, but a repeat of the PCR analysis
produced similar results. In both tests, all controls per-
formed as expected, and no general contamination was
evident in the reagents. If robust, these results could
only be explained biologically if the majority of infec-
tions were a mix of CVIET and CVMNK parasites, with
the latter usually undetectable at day 0. Drug effects
may then have led to release of dead or damaged
sequestered parasites (including gametocytes), and
resulting in a small “blip” of CVMNK DNA being
detected in the peripheral blood of most individuals, as
well as the more resistant and abundant CVIET type.
Recent studies showing the detection of P. falciparum
DNA in the saliva of infected people may indicate the
transient retention of parasite DNA in buccal macro-
phages [31,32], and thus phagocytes in the peripheral
circulation may also provide a short-lived DNA signal
from drug-killed P. falciparum killed in sequestered
niches. This would again suggest that a single PCR
amplification from peripheral blood at day 0 provides a
poor representation of the parasite diversity present in
an infected individual.
Apart from this question, the major weaknesses of the
study were, firstly, that absolute quantification could not
be performed due to variability in the volume of blood
collected onto blood-spots, and to the use of two differ-
ent types of filter paper. In future studies this will be
rectified so that a direct comparison can be made
between relative quantification methods, as used here,
and absolute quantification against the international
P. falciparum DNA standard [33]. Secondly, the assay
employed shares with most PCR methods a tendency to
miss those mixed genotype infections where one geno-
type is substantially more abundant than the other. This
is because the amplified targets of the three allele-speci-
fic probes share amplification primers, and therefore the
exponential amplification dynamics will lead to an over-
representation of the abundant species, and a paucity of
the rare species. This is demonstrated by two additional
mixed infections with a low abundance of parasites with
the CVMNK genotype being identified in the triplicate
quantitative analysis. Both of these individuals had been
typed as harbouring CVIET genotypes only in our initial
qualitative analysis, which employs a conservative
threshold to maximise specificity rather than sensitivity.
The current deployment of ACT for anti-malarial treat-
ment across the African continent suggests that the acute
crisis precipitated by spreading parasite resistance to
chloroquine and sulphadoxine-pyrimethamine is being
averted [1]. The use of ACT is likely to contribute to con-
tinuing reductions in malaria-related morbidity and mor-
tality, such as those recently reported in The Gambia and
coastal Kenya [34,35]. ACT is also threatened by the devel-
opment of resistance [36,37]. Careful monitoring of the
immediate quantitative effects of combination drugs on
parasite burden in the first few days after treatment is
therefore advisable to detect any delay in parasite clear-
ance that may signal a reduction in drug efficacy.
Conclusions
Evidence was presented that minor populations of drug
resistant parasites are rapidly selected in the first 24
Gadalla et al. Malaria Journal 2010, 9:74
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Page 8 of 10hours of antimalarial treatment in vivo. Thus a single
pre-treatment parasite sample does not fully represent
the within-host parasite population from which later
recrudescent parasitaemia can arise.
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